Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Models for Drug Testing: Organoids & Tissue Chips 2022

Thomas Gervais's Biography

Thomas Gervais, Professor of Engineering Physics and Biomedical Engineering, Ecole Polytechnique de Montréal

Thomas Gervais is professor of engineering physics and biomedical engineering at Polytechnique Montreal and researcher at the Centre Hospitalier de l’Université de Montréal (CHUM). He is also a member of the Montreal Cancer Institute (ICM). His research deals with fluid physics and transport phenomena at the microscale, and the development of lab-on-a-chip strategies to accelerate discovery or improve treatment in oncology. He is co-founder of the CHUM’s Microfluidic Core Facility and of MISO Chip Inc., a laboratory spin-off seeking to develop microfluidic tools to culture and analyze primary tumors. He holds a bachelor’s degree from Polytechnique Montreal in Engineering Physics and a Ph.D. in bioengineering from the Massachusetts Institute of Technology.

Thomas Gervais Image

Microdissected Tissue Processing Using Open-Space and Closed Microfluidics – From First Principles Design to Drug Testing

Wednesday, 14 September 2022 at 09:30

Add to Calendar ▼2022-09-14 09:30:002022-09-14 10:30:00Europe/LondonMicrodissected Tissue Processing Using Open-Space and Closed Microfluidics – From First Principles Design to Drug Testing3D-Models for Drug Testing: Organoids and Tissue Chips 2022 in

The inability to adequately predict the response of a given patient to therapeutic agents is a major, longstanding challenge in clinical oncology. In the past decade, there has been a major push to develop ex vivo platforms to directly probe the response of a patient’s tumor to a panel of drug candidates in order to optimize drug prescription and treatment response. Due to their small sizes, versatility and precise control of the culture microenvironment, microfluidics systems have emerged as a promising approach to develop such platforms. Yet, several challenges must be solved to ensure on-chip tumor viability, simplicity of use, throughput, and to deliver quality readouts for clinical decision making. In this talk, we will discuss the concept of micro-dissected tissue (MDT) as an emerging on-chip ex vivo model that is both simple to use, and compatible with current gold standard histopathology readouts. We will introduce two platforms, drawing upon classical and open-space microfluidics, for processing them and a general method to bridge the gap between MDT processing and gold-standard histopathology. Our results set the base for a complete micro-histological platform compatible with most solid tumour cancers, that provides the equivalent of tissue microarrays to assay individual response to drugs.

Add to Calendar ▼2022-09-13 00:00:002022-09-14 00:00:00Europe/London3D-Models for Drug Testing: Organoids and Tissue Chips 20223D-Models for Drug Testing: Organoids and Tissue Chips 2022 in